According to a report in China Daily on February 10, 2026
Innovent Biologics has entered a strategic collaboration with US pharmaceutical giant Eli Lilly to jointly develop innovative medicines in oncology and immunology, underscoring the growing integration of China’s biopharma sector into the global innovation ecosystem.
Under the agreement, Innovent will receive $350 million upfront, with potential development, regulatory, and commercial milestone payments of up to $8.5 billion. Innovent will lead research and development in China from drug discovery through Phase II proof-of-concept clinical trials, reflecting a shift in which multinational firms increasingly engage with early-stage Chinese innovation rather than waiting for late-stage validation.
Yu Dechao, Innovent’s founder and CEO, said:
“This alliance moves beyond traditional licensing to create an end-to-end innovation ecosystem, combining our agile discovery and early-stage development capabilities with Lilly’s global scale. It validates Innovent’s R&D capabilities and commitment to improving patient outcomes.”
The deal illustrates a common pattern in Chinese biopharma globalization: domestic companies license overseas rights while retaining China commercial rights, maintaining a strong domestic presence while expanding globally.
According to China’s National Medical Products Administration, out-licensing transactions by Chinese innovative drugmakers reached $135.7 billion in 2025 across 157 deals, up sharply from $51.9 billion in 2024. The largest deals were concentrated in oncology immunotherapy, antibody-drug conjugates, and other advanced modalities, with increasing collaboration in earlier-stage assets and deeper R&D integration.
Zhang Fangning, a partner at McKinsey & Company, noted:
“China has become a meaningful source of innovation for global companies. Out-licensing is now part of a broader globalization strategy, where the depth of the pipeline and the ecosystem’s ability to integrate globally are key.”
This partnership highlights both China’s rising role in global biopharmaceutical innovation and the expanding opportunities for multinational collaborations with domestic R&D leaders.